Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 21, Issue 1, 2007, Pages 131-144

  Toumpanakis, Christos ^a   Meyer, Tim ^a   Caplin, Martyn E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

carcinoids; chemoembolization; chemotherapy; cytotoxic treatment; liver metastases; neuroendocrine tumours; particle embolization

Indexed keywords

ALCOHOL; ALLOPURINOL; ANALGESIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CARBOPLATIN; CARMUSTINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROCORTISONE; IFOSFAMIDE; IRINOTECAN; OCTREOTIDE; PACLITAXEL; PENTETREOTIDE; STREPTOZOCIN; VINCRISTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ALLERGIC REACTION; ARTERIOGRAPHY; ARTERY CATHETERIZATION; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRYOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; GASTRINOMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TUMOR; GLUCAGONOMA; HEMATOLOGIC DISEASE; HEPATIC ARTERY LIGATION; HEPATOMEGALY; HUMAN; INSULINOMA; INTESTINE TUMOR; LIVER METASTASIS; LUNG CARCINOMA; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PANCREAS TUMOR; PHEOCHROMOCYTOMA; RADIOFREQUENCY ABLATION; RENAL PROTECTION; REVIEW; SEPSIS; STOMACH CARCINOID; SURVIVAL TIME; THYMOMA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR LYSIS SYNDROME; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC AGENTS; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HUMANS; NEUROENDOCRINE TUMORS; TREATMENT OUTCOME;

EID: 33947240452     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.01.005     Document Type: Review

References (61)

1. nd: Carcinoid tumours: A 37-year experience. Archives of Surgery 117 (1982) 732-737
2. Mc Dermott E.W., Guduric B., and Brennan M.F. Prognostic variables in patients with gastrointestinal carcinoid tumours. The British Journal of Surgery 81 (1994) 1007-1009
3. McEntee G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive surgery for neuroendocrine tumours. Surgery 108 (1990) 1091-1096
4. Shah T., and Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Practice & Research. Clinical Gastroenterology 19 4 (2005 Aug) 617-636
5. Solcia E., Kloppel G., Sobin L.H., et al. Histological typing of endocrine tumors. WHO international histological classification of tumors. 2nd ed. (2000), Springer, Berlin
6. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 3 (2000 Feb 2) 205-216
7. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine 326 8 (1992 Feb 20) 519-523
8. Warner R.R. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128 6 (2005 May) 1668-1684
9. Arnold R., Rinke A., Schmidt C., and Hofbauer L. Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Practice & Research. Clinical Gastroenterology 19 4 (2005 Aug) 649-656
10. Modlin I.M., Kidd M., Latich I., et al. Current status of gastrointestinal carcinoids. Gastroenterology 128 6 (2005 May) 1717-1751
11. Murray-Lyon I.M., Eddleston A.L., Williams R., et al. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2 7574 (1968 Oct 26) 895-898
12. Sun W., Lipsitz S., Catalano P., et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 22 (2005 Aug 1) 4897-4904
13. Moertel C.G., Lavin P.T., and Hahn R.G. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treatment Reports 66 7 (1982 Jul) 1567-1569
14. Ansell S.M., Pitot H.C., Burch P.A., et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 8 (2001 Apr 15) 1543-1548
15. Kulke M.H., Kim H., Stuart K., et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Investigation 22 3 (2004) 353-359
16. Kulke M.H., Kim H., Clark J.W., et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101 5 (2004 Sep 1) 934-939
17. Moertel C.G., Hanley J.A., and Johnson L.A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. The New England Journal of Medicine 303 21 (1980 Nov 20) 1189-1194
18. Eriksson B., Skogseid B., Lundqvist G., et al. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 9 (1990 May 1) 1883-1890
19. Bukowski R.M., Tangen C., Lee R., et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology 10 12 (1992 Dec) 1914-1918
20. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 6 (1999 Sep 15) 944-948
21. McCollum A.D., Kulke M.H., Ryan D.P., et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. American Journal of Clinical Oncology 27 5 (2004 Oct) 485-488
22. Delaunoit T., Ducreux M., Boige V., et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?. European Journal of Cancer 40 4 (2004 Mar) 515-520
23. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 23 (2004 Dec 1) 4762-4771
24. von Schrenck T., Howard J.M., Doppman J.L., et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 94 6 (1988 Jun) 1326-1334
25. Ruszniewski P., Hochlaf S., Rougier P., and Mignon M. Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients. Gastroentérologie Clinique et Biologique 15 5 (1991) 393-398
26. O'Toole D., Hentic O., Corcos O., and Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80 supplement 1 (2004) 79-84
27. Moertel C.G., and Hanley J.A. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials 2 4 (1979 Winter) 327-334
28. Engstrom P.F., Lavin P.T., Moertel C.G., et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology 2 11 (1984 Nov) 1255-1259
29. Bukowski R.M., Johnson K.G., Peterson R.F., et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60 12 (1987 Dec 15) 2891-2895
30. Moertel C.G., Kvols L.K., O'Connell M.J., and Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 2 (1991 Jul 15) 227-232
31. Mitry E., Baudin E., Ducreux M., et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 81 8 (1999 Dec) 1351-1355
32. Fjallskog M.L., Granberg D.P., Welin S.L., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 5 (2001 Sep 1) 1101-1107
33. Hou Z., Elasmar A., Lozano R., et al. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proceedings of American Society of Clinical Oncology 22 (2003) A1508
34. Janmohamed S., O'Shea D., and Bloom S. Bronchial and thymic neuroendocrine tumours. In: Sheaves R., Jenkins P.J., and Wass J.A.H. (Eds). Clinical endocrine oncology (1997), Blackwell Science, Oxford 403-410
35. Postmus P.E., and Smit E.F. Small-cell lung cancer: is there a standard therapy?. Oncology (Huntigt) 12 (1998) 25-30
36. Sandler A.B. Etoposide plus ifosphamide plus cisplatin in the treatment of small cell lung cancer. Seminars in Oncology 25 (1998) 38-41
37. Averbuch S.D., Steakley C.S., Young R.C., et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of Internal Medicine 109 4 (1988 Aug 15) 267-273
38. Ahlman H., Nilsson O., and Olausson M. Interventional treatment of the carcinoid syndrome. Neuroendocrinology 80 supplement 1 (2004) 67-73
39. Allison D.J., Modlin I.M., and Jenkins W.J. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet 2 8052-8053 (1977 Dec 24-31) 1323-1325
40. O'Toole D., and Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Practice & Research. Clinical Gastroenterology 19 4 (2005 Aug) 585-594
41. Ruszniewski P., and O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 80 supplement 1 (2004) 74-78
42. Ramage J.K., Davies A.H., Ardill J., et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54 supplement 4 (2005 Jun) iv1-iv16
43. de Herder W.W., Krenning E.P., Van Eijck C.H., and Lamberts S.W. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocrine-related Cancer 11 1 (2004 Mar) 19-34
44. Eriksson B.K., Larsson E.G., Skogseid B.M., et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 11 (1998 Dec 1) 2293-2301
45. Ruszniewski P., Rougier P., Roche A., et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71 8 (1993 Apr 15) 2624-2630
46. Roche A., Girish B.V., de Baere T., et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Radiology 13 1 (2003 Jan) 136-140
47. Kim Y.H., Ajani J.A., Carrasco C.H., et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Investigation 17 7 (1999) 474-478
48. Nesovic M., Ciric J., Radojkovic S., et al. Improvement of metastatic endocrine tumors of the pancreas by hepatic artery chemoembolization. Journal of Endocrinological Investigation 15 7 (1992 Jul-Aug) 543-547
49. D'Alteroche L., Viguier J., Maillard H., et al. Chemoembolization followed by systemic chemotherapy with dacarbazine for a metastatic glucagonoma. Gastroentérologie Clinique et Biologique 24 1 (2000 Jan) 132-133
50. Drougas J.G., Anthony L.B., Blair T.K., et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. American Journal of Surgery 175 5 (1998 May) 408-412
51. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 8 (2005 Oct 15) 1590-1602
52. Moertel C.G., Johnson C.M., McKusick M.A., et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine 120 4 (1994 Feb 15) 302-309
53. McStay M.K., Maudgil D., Williams M., et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 237 2 (2005 Nov) 718-726
54. Popperl G., Helmberger T., Munzing W., et al. Selective Internal Radiation Therapy with SIR-Spheres in Patients with Nonresectable Liver Tumours. Cancer Biotherapy & Radiopharmaceuticals 20 2 (2005 Apr) 200-208
55. Livraghi T., Vettori C., and Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 179 3 (1991 Jun) 709-712
56. Shafir M., Shapiro R., Sung M., et al. Cryoablation of unresectable malignant liver tumors. American Journal of Surgery 171 1 (1996 Jan) 27-31
57. Cozzi P.J., Englund R., and Morris D.L. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 76 3 (1995 Aug 1) 501-509
58. Seifert J.K., Cozzi P.J., and Morris D.L. Cryotherapy for neuroendocrine liver metastases. Seminars in Surgical Oncology 14 2 (1998 Mar) 175-183
59. Wessels F.J., and Schell S.R. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. The Journal of Surgical Research 95 1 (2001 Jan) 8-12
60. Hellman P., Ladjevardi S., Skogseid B., et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World Journal of Surgery 26 8 (2002 Aug) 1052-1056
61. Berber E., Flesher N., and Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World Journal of Surgery 26 8 (2002 Aug) 985-990